Key metrics to watch: Fee-related earnings (FRE) and FRE margin - core profitability excluding carry volatility · Fundraising totals and fee-paying AUM growth - forward revenue visibility · Deployment and realization volumes - capital activity driving future and current carry · Fee-paying AUM growth rate (target 15-20% annually)

News

uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

prnewswire.com

Kyndryl Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - KD

prnewswire.com

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

prnewswire.com

Driven Brands Holdings Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DRVN

prnewswire.com

Eos Energy Enterprises, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EOSE

prnewswire.com

Plug Power Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PLUG

prnewswire.com

InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 20

accessnewswire.com

Hellman's mayonnaise maker Unilever in takeover talks with McCormick for food business

reuters.com

PLUG Investors Have Opportunity to Lead Plug Power Inc. Securities Fraud Lawsuit with the Schall Law Firm

prnewswire.com

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

prnewswire.com

Apollo Global Management, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - APO

prnewswire.com

Prediction: This Will Be Amazon's Stock Price in 5 Years

fool.com

The Iran war is sending shockwaves through the world's busiest IPO market

cnbc.com

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

wsj.com

Transaction in Own Shares

globenewswire.com

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

businesswire.com

About

founded in 1976 and led by henry kravis and george roberts, kkr is a leading global investment firm that manages investments across multiple asset classes including private equity, energy, infrastructure, real estate, credit and hedge funds.

CEO

Joseph Bae

kkr.com/ →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

Kyndryl Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - KD

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

Driven Brands Holdings Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DRVN

Eos Energy Enterprises, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EOSE

Plug Power Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PLUG

InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 20

Hellman's mayonnaise maker Unilever in takeover talks with McCormick for food business

PLUG Investors Have Opportunity to Lead Plug Power Inc. Securities Fraud Lawsuit with the Schall Law Firm

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

McCormick Issues Statement

Serbia secures US sanctions waiver for its NIS oil firm, energy minister says

Notice of Full Year Results and Investor Presentation

Morningstar Awards for Investing Excellence UK 2026: Winners Announced

Apollo Global Management, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - APO

Prediction: This Will Be Amazon's Stock Price in 5 Years

The Iran war is sending shockwaves through the world's busiest IPO market

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Transaction in Own Shares

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

About

Explore More

uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

Kyndryl Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - KD

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

Driven Brands Holdings Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DRVN

Eos Energy Enterprises, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EOSE

Plug Power Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PLUG

InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 20

Hellman's mayonnaise maker Unilever in takeover talks with McCormick for food business

PLUG Investors Have Opportunity to Lead Plug Power Inc. Securities Fraud Lawsuit with the Schall Law Firm

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

McCormick Issues Statement

Serbia secures US sanctions waiver for its NIS oil firm, energy minister says

Notice of Full Year Results and Investor Presentation

Morningstar Awards for Investing Excellence UK 2026: Winners Announced

Apollo Global Management, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - APO

Prediction: This Will Be Amazon's Stock Price in 5 Years

The Iran war is sending shockwaves through the world's busiest IPO market

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Transaction in Own Shares

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®